Suggested remit: To appraise the clinical and cost effectiveness of brentuximab vedotin in combination, within its marketing authorisation for treating untreated advanced classical Hodgkin lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6437
Provisional Schedule
- Committee meeting: 1:
- 12 January 2027
- Expected publication:
- 06 May 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- Takeda UK (brentuximab vedotin)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer52
- Follicular Lymphoma Foundation
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Leukaemia UK
- Lymphoma Action
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- WMUK
- Professional groups
- Association of Cancer Physicians
- British Blood Transfusion Society
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- British Society of Blood and Marrow Transplantation and Cellular Therapy
- British Society of Interventional Radiology
- British Transplantation Society
- Cancer Research UK
- NHS Blood and Transplant
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Cutaneous Lymphoma Group
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Accord‑UK (bleomycin, doxorubicin, etoposide)
- Baxter Healthcare (cyclophosphamide, doxorubicin)
- Fresenius Kabi (etoposide)
- Hikma Pharmaceuticals International (doxorubicin, etoposide)
- Medac UK (dacarbazine, doxorubicin)
- Neon Healthcare (bleomycin, etoposide)
- Pfizer (doxorubicin, vinblastine, vincristine)
- Sandoz (cyclophosphamide)
- Seacross Pharmaceuticals (cyclophosphamide, doxorubicin)
- Sun Pharma UK (doxorubicin)
- Teva UK (vincristine)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematology Group
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- Lymphoma Research Trust
- MRC Clinical Trials Unit
- National Cancer Research Institute High Grade Lymphoma Subgroup
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 June 2026 | Invitation to participate |
| 13 March 2026 - 14 April 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6437 |
| 13 March 2026 | In progress. Scoping commencing |
| 12 December 2024 | Referral |
| 28 February 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual